ReviewEuropean journal of heart failure2022
Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum.
Review in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05093933 (A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Vericiguat in patients with heart failure across the spectrum of left ventricular ejection fraction: a patient-level, pooled meta-analysis of VITALITY-HFpEF and VICTORIA.Frontiers in endocrinology · 2024Pooled it
- Improving therapeutic outcomes in heart failure with reduced nonvalvular ejection fraction: A clinical study of heart failure education intervention.Clinical cardiology · 2024Trial
- DAPT Mitigates Osteoarthritic Cartilage Degeneration and Enhances Articular Repair Through Targeted Modulation of the Gucy1a3 and Notch Signaling Axis.Drug design, development and therapy · 2026Article
- Victoria and Victor: event-driven lessons for integrating vericiguat into practice and reducing residual risk in HFrEF.Heart failure reviews · 2025Review
- Review
- Implementation of guideline-recommended medical therapy for patients with heart failure in Europe.ESC heart failure · 2025Review
- 2024 update in heart failure.ESC heart failure · 2025Review
- Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial.European journal of heart failure · 2025Article
- New Therapeutics for Heart Failure Worsening: Focus on Vericiguat.Journal of clinical medicine · 2024Review
- Novel Medical Treatments and Devices for the Management of Heart Failure with Reduced Ejection Fraction.Journal of cardiovascular development and disease · 2024Review
- Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode.ESC heart failure · 2024Review
- Soluble guanylate cyclase stimulators for heart failure: a network meta-analysis and subgroup analyses of reduced and preserved ejection fraction.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2024Article
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of a soluble guanylate cyclase stimulator, HEC95468, in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial.Frontiers in pharmacology · 2024Article
- New Challenges in Heart Failure with Reduced Ejection Fraction: Managing Worsening Events.Journal of clinical medicine · 2023Review
- Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction.Journal of cardiovascular development and disease · 2023Review
- Heart failure therapy: the fifth card.European heart journal supplements : journal of the European Society of Cardiology · 2023Article
- Corrigendum to: 'An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum' and articles listed below.European journal of heart failure · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
19 authors at 15 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with heart failure with reduced ejection fraction (HFrEF) have a high residual risk of adverse outcomes, even when treated with optimal guideline-directed medical therapy and in a clinically stable state. Soluble guanylate cyclase (sGC) stimulators have the potential to lower this risk by modifying the nitric oxide-sGC-cyclic guanosine monophosphate cascade - a pathophysiological pathway that has been targeted with limited success in HFrEF previously. Vericiguat, an sGC stimulator, was shown to improve outcomes in patients with HFrEF in the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. However, this trial included patients with recently worsening disease. In this brief review, we discuss the rationale of evaluating sGC stimulators in lower-risk HFrEF patients. First, all key HFrEF medications have been evaluated in both higher- and lower-risk populations, and the treatment effect is not always consistent across the risk spectrum. Second, pre-clinical studies and post-hoc studies of the VICTORIA trial have suggested that sGC stimulators may have cardioprotective effects - these effects may be more apparent when the medication is initiated earlier in the disease process. Third, the effect of vericiguat on cardiovascular mortality remains uncertain and a trial with a longer follow-up in a lower-risk population may allow better assessment of its effect on cardiovascular mortality. Therefore, there is a pertinent need to investigate the effects of vericiguat in optimally treated, low-risk HFrEF patients (i.e. those without recently worsening heart failure).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.